Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Integration of FTT-PET and ctDNA to Predict Response to PARP Inhibitor Therapy in Metastatic Prostate Cancer (mPC)

NCT07723651 is registered in ClinicalTrials.gov with Washington University School of Medicine as lead sponsor.

NCT NCT07723651
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07723651 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Integration of FTT-PET and ctDNA to Predict Response to PARP Inhibitor Therapy in Metastatic Prostate Cancer (mPC)
Lead sponsor
Washington University School of Medicine
Phase
Phase 2
Overall status
Not yet recruiting
Start date
September 1, 2026
Completion date
March 31, 2032
Enrollment
75 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic prostate cancer, prostate cancer